N-acetyl Cysteine and Patients with Non-alcoholic Fatty Liver Disease
Phase 3
Completed
- Conditions
- Simple Steatosis Non Fatty Liver
- Interventions
- Drug: N acetyl cysteine with weight reduction
- Registration Number
- NCT05589584
- Lead Sponsor
- Ain Shams University
- Brief Summary
Effect of N-acetyl cysteine on markers of oxidative stress and insulin resistance in patients with Non-alcoholic fatty liver disease
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- Males or females aged 18-60 years diagnosed with NAFLD
Exclusion Criteria
- History of alcohol consumption, drug addiction or the use of medications known to precipitate steatohepatitis.
- Patients with schistosomiasis, active hepatitis B or C, autoimmune and diabetes mellitus.
- current Consumption of any antioxidant supplements and hepatotoxic drug.
- Pregnancy or lactation or expecting to get pregnant during the study.
- Medical, psychological, or pharmacological factors interfering with the collection or interpretation of study data.
- Active Cancer patients.
- Anyone having hypersensitivity to N-acetylcysteine.
- Anyone already taking N-acetylcysteine.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description intervention N acetyl cysteine with weight reduction NAC and weight reduction program
- Primary Outcome Measures
Name Time Method assessment of the effect of NAC on leptin 3 months leptin as insulin resistance marker in NAFLD
- Secondary Outcome Measures
Name Time Method assessment of the effect of NAC on MDA 3 months MDA as oxidative stress marker in NAFLD
Trial Locations
- Locations (1)
NHTMRI
🇪🇬Cairo, Egypt